DE60234193D1 - Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen - Google Patents

Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen

Info

Publication number
DE60234193D1
DE60234193D1 DE60234193T DE60234193T DE60234193D1 DE 60234193 D1 DE60234193 D1 DE 60234193D1 DE 60234193 T DE60234193 T DE 60234193T DE 60234193 T DE60234193 T DE 60234193T DE 60234193 D1 DE60234193 D1 DE 60234193D1
Authority
DE
Germany
Prior art keywords
geneva
bindings
disulphide
constructed
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234193T
Other languages
English (en)
Inventor
John H Griffin
Andrew J Gale
Elizabeth D Getzoff
Jean-Luc Pellequer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE60234193D1 publication Critical patent/DE60234193D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60234193T 2001-06-14 2002-06-14 Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen Expired - Lifetime DE60234193D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29857801P 2001-06-14 2001-06-14
PCT/US2002/019017 WO2002103024A2 (en) 2001-06-14 2002-06-14 Stabilized proteins with engineered disulfide bonds

Publications (1)

Publication Number Publication Date
DE60234193D1 true DE60234193D1 (de) 2009-12-10

Family

ID=23151124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234193T Expired - Lifetime DE60234193D1 (de) 2001-06-14 2002-06-14 Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen

Country Status (8)

Country Link
US (2) US7205278B2 (de)
EP (2) EP1421539B1 (de)
JP (2) JP4361786B2 (de)
AU (1) AU2002310438B2 (de)
CA (1) CA2450732A1 (de)
DE (1) DE60234193D1 (de)
ES (1) ES2331909T3 (de)
WO (1) WO2002103024A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002310438B2 (en) * 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1502921A1 (de) * 2003-07-29 2005-02-02 ZLB Behring GmbH Rekombinanter mutierter menschlicher Factor VIII (FVIII) mit verbesserter Stabilität
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
US20060019893A1 (en) * 2004-07-02 2006-01-26 Genentech, Inc. Factor VIIa variants
KR101654011B1 (ko) 2004-11-12 2016-09-05 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
AU2006233638A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
EP2081589B1 (de) * 2006-11-16 2010-10-06 Crucell Holland B.V. Komplementierung von faktor xi-mangel durch faktor v-mutanten
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
KR20100113478A (ko) * 2007-11-01 2010-10-21 유니버시티 오브 로체스터 증가된 안정성을 갖는 재조합 인자 ⅴⅰⅰⅰ
EP2291523B1 (de) 2008-06-24 2014-12-17 CSL Behring GmbH Faktor VIII, Von-Willebrand-Faktor oder Komplexe davon mit verlängerter in-vivo-Halbwertzeit
ES2542202T3 (es) * 2009-01-22 2015-08-03 Novo Nordisk Health Care Ag Compuestos de hormonas de crecimiento estables
WO2011053169A1 (en) * 2009-10-30 2011-05-05 Agresearch Limited Modified oil encapsulating proteins and uses thereof
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
JP5875527B2 (ja) 2010-01-22 2016-03-02 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
WO2012010516A1 (en) * 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
JP2016518321A (ja) * 2013-03-15 2016-06-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組み換え因子ｖｉｉｉ配合物
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2015066700A2 (en) 2013-11-04 2015-05-07 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
EP3164150B1 (de) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Modifizierter von-willebrand-faktor
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
EP3298036B1 (de) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
RU2017145014A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
CN104974228B (zh) * 2015-06-15 2017-10-17 四川合泰新光生物科技有限公司 一种小分子多肽zy4及其应用
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
EP3538133B1 (de) 2016-11-11 2021-02-17 CSL Behring Lengnau AG Verkürzte von-willebrand-faktor-polypeptide zur behandlung von hämophilie
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
US11788081B2 (en) 2018-04-19 2023-10-17 Stichting Vu Protein macrocyclization
EP3810647A4 (de) * 2018-04-26 2022-08-17 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen zur behandlung von hämophilie

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5009889A (en) 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US4852871A (en) * 1988-12-02 1989-08-01 John Perko Hand exercise device
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5610137A (en) 1990-12-20 1997-03-11 The Uab Research Foundation Transgenic, cross-linked hemoglobin
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5114148A (en) * 1991-07-09 1992-05-19 Liu Ming Zen Puzzle device
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5453937A (en) 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5543149A (en) * 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AU2002310438B2 (en) * 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds

Also Published As

Publication number Publication date
JP2008271975A (ja) 2008-11-13
US7928199B2 (en) 2011-04-19
EP1421539A4 (de) 2005-11-09
JP2005500831A (ja) 2005-01-13
US7205278B2 (en) 2007-04-17
EP2110385A8 (de) 2010-06-02
EP1421539B1 (de) 2009-10-28
AU2002310438B2 (en) 2008-05-01
EP1421539A2 (de) 2004-05-26
WO2002103024A3 (en) 2004-03-18
US20030125232A1 (en) 2003-07-03
EP2110385A1 (de) 2009-10-21
WO2002103024A2 (en) 2002-12-27
US20070276128A1 (en) 2007-11-29
JP4361786B2 (ja) 2009-11-11
CA2450732A1 (en) 2002-12-27
ES2331909T3 (es) 2010-01-20

Similar Documents

Publication Publication Date Title
DE60234193D1 (de) Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
DE60204410D1 (de) Keilförmiges Gewinde mit Drehemomentshulter
DK1421841T3 (da) Mejetærsker
DE60224791D1 (de) Gewindeverbindung
DE60213194D1 (de) Haltenadel mit flügel
DE60218081D1 (de) Markierungsteilchen
DE50212845D1 (de) Kunstharzpalette
ATE286478T1 (de) Verschlusskappe
DE50212108D1 (de) Substituierte fluoralkoxyphenylsulfonylharnstoffe
GB2376865B (en) Birdhouse with deployable fledging board
DE60206798D1 (de) Stabilisierte harzzusammensetzungen
HK1043912A2 (en) Huqin with added strings
DE60134712D1 (de) Regulierventil
DE60238850D1 (de) Rattenmodell mit regucalcin-überexpression
DE50203426D1 (de) Steuerknüppel
ATE303835T1 (de) Spritze
ATE296652T1 (de) Spritze
ES1049379Y (es) Paraguas
UA5432S (uk) Пенал
TH52276EX (th) ดินสอ
TH52273EX (th) ดินสอ
FI4971U1 (fi) Kangaspuut
FIU20010300U0 (fi) Salibandymaila
SE0100582D0 (sv) Point
SE0102895D0 (sv) Plockare

Legal Events

Date Code Title Description
8364 No opposition during term of opposition